Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus
about
HIV-1 induced bystander apoptosisSingle-Cell and Single-Cycle Analysis of HIV-1 ReplicationStructures and Mechanisms of Viral Membrane Fusion Proteins: Multiple Variations on a Common ThemeV3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodiesAsymmetric deactivation of HIV-1 gp41 following fusion inhibitor bindingImpact of the HIV-1 env genetic context outside HR1-HR2 on resistance to the fusion inhibitor enfuvirtide and viral infectivity in clinical isolatesHIV/AIDS epidemiology, pathogenesis, prevention, and treatmentDevelopment of a High-Throughput Functional Screen Using Nanowell-Assisted Cell PatterningDC-SIGN increases the affinity of HIV-1 envelope glycoprotein interaction with CD4.Physiological levels of virion-associated human immunodeficiency virus type 1 envelope induce coreceptor-dependent calcium flux.A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity.Elite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kineticsInhibition of HIV-1 entry by extracts derived from traditional Chinese medicinal herbal plantsEarly steps of HIV-1 fusion define the sensitivity to inhibitory peptides that block 6-helix bundle formation.Rapid dissociation of HIV-1 from cultured cells severely limits infectivity assays, causes the inactivation ascribed to entry inhibitors, and masks the inherently high level of infectivity of virions.Variants of human immunodeficiency virus type 1 that efficiently use CCR5 lacking the tyrosine-sulfated amino terminus have adaptive mutations in gp120, including loss of a functional N-glycanEntry kinetics and cell-cell transmission of surface-bound retroviral vector particles.Fitness epistasis and constraints on adaptation in a human immunodeficiency virus type 1 protein regionAdoption of an "open" envelope conformation facilitating CD4 binding and structural remodeling precedes coreceptor switch in R5 SHIV-infected macaques.Time-resolved imaging of HIV-1 Env-mediated lipid and content mixing between a single virion and cell membrane.Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodiesCCR5 antagonists: host-targeted antivirals for the treatment of HIV infection.CCR5 antibodies HGS004 and HGS101 preferentially inhibit drug-bound CCR5 infection and restore drug sensitivity of Maraviroc-resistant HIV-1 in primary cells.An alteration of human immunodeficiency virus gp41 leads to reduced CCR5 dependence and CD4 independence.Different infectivity of HIV-1 strains is linked to number of envelope trimers required for entryRole of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patientsHIV ENV glycoprotein-mediated bystander apoptosis depends on expression of the CCR5 co-receptor at the cell surface and ENV fusogenic activitySelection with a peptide fusion inhibitor corresponding to the first heptad repeat of HIV-1 gp41 identifies two genetic pathways conferring cross-resistance to peptide fusion inhibitors corresponding to the first and second heptad repeats (HR1 and HHIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drugA Conserved Glycan in the C2 Domain of HIV-1 Envelope Acts as a Molecular Switch to Control X4 Utilization by Clonal Variants with Identical V3 Loops.The second extracellular loop of CCR5 contains the dominant epitopes for highly potent anti-human immunodeficiency virus monoclonal antibodies.Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro.Stochastic entry of enveloped viruses: fusion versus endocytosisConserved changes in envelope function during human immunodeficiency virus type 1 coreceptor switchingKinetic mechanism for HIV-1 neutralization by antibody 2G12 entails reversible glycan binding that slows cell entry.Short Communication: HIV-1 Variants That Use Mouse CCR5 Reveal Critical Interactions of gp120's V3 Crown with CCR5 Extracellular Loop 1CCR5 Expression Levels in HIV-Uninfected Women Receiving Hormonal Contraception.Receptor Activation of HIV-1 Env Leads to Asymmetric Exposure of the gp41 Trimer.Role of gp120 trimerization on HIV binding elucidated with Brownian adhesive dynamicsMonitoring early fusion dynamics of human immunodeficiency virus type 1 at single-molecule resolution.
P2860
Q22241221-90A246DF-8DCC-424B-81B0-FCE4999B08B1Q27319151-186F5DCC-0807-49FA-9678-23B0CEF1D612Q27487974-FDA9DF77-A487-4635-A542-AB8E48D8CCEFQ28469283-55E021D3-A94D-41C6-BC95-DBC9037CADBCQ28471980-A99B5FB1-D9F9-4FBA-855A-EC0A665528B9Q28478943-AC7D6570-6434-47C0-8075-40999C72CD95Q30356074-A095B612-A0C1-43AE-A176-E4C1EC3A5C26Q30375510-2C990B77-6A50-4A6E-A2D9-163D136EAB37Q30472149-75FB1D8A-57F4-4AFF-B707-B1CFBCC375B5Q30478990-683B0CA0-06F7-4D20-A9CB-5BCABA26FC3CQ30654651-89607721-D6E5-4D71-A875-EBD644021599Q33429049-C7D9B65A-926E-4E1B-BC08-C912F1C2922FQ33490833-844B83F5-2BC6-4529-8895-ECD76EEEAD95Q33504556-615661D5-C080-4B15-B970-FCB642BB3779Q33676520-1D497AFF-1CE5-4E14-B965-93DD54B8574FQ33707333-6AA80196-6DDC-47B6-9682-FDCB37301074Q33831103-65A60427-E256-4772-B8EA-20642FF427C7Q33853183-0EA9B694-4A50-4659-8465-C46179B2211DQ33961448-69EBE66C-2AF7-4A2E-9543-773248865738Q34148120-29915FAF-0FA7-4C0B-B5CC-D56906784361Q34229664-4370EE07-13E0-4237-A863-83F539FCC1BBQ34473072-139DB40D-44C4-4334-B2C3-43E401D2D93CQ34574397-218BC353-6F93-41F4-88FB-475FF2239652Q34763384-29C59663-5887-47D6-A754-7D00EB5F6C5BQ34875765-3D36D64F-0487-4899-8433-FA76635E8AD3Q35024183-E8DE4F63-8227-479A-81FA-30FB06086196Q35378551-404B6108-6A86-44B4-AD63-BDE602B64853Q35599288-C80BFF67-2F06-4920-9032-EDCCA960C2F7Q35665842-DD73038A-C131-44FC-A4BC-0434310AE5DAQ35666270-34FCA466-7FC4-4791-B808-67CCE4077301Q35758790-94C1102A-1697-435D-87B3-3AC443147CAAQ35878870-8D6E5F58-FFBF-4CA8-B5BA-6FCA0618437CQ35906141-08C983F6-0B59-4B96-8880-F0012A88FA06Q35947621-17A40A2F-FB62-4E4C-898A-67C14FFD1021Q35974165-6E18757F-4876-4D7E-8D89-E8E1DF7523F2Q36078450-8FA05188-7AAE-41A8-855E-68C001C02203Q36149013-9AFD4961-06F7-4C1B-A173-FED078A00FACQ36228646-82DF60EC-A091-4E29-B08D-F97B8D47C822Q36717705-D9020FFE-7C6A-4ACC-A21F-FB6331F6AECFQ36747741-62073E55-846F-4B70-B87D-E06C65B0A2FF
P2860
Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus
description
2005 nî lūn-bûn
@nan
2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Kinetic factors control effici ...... f human immunodeficiency virus
@ast
Kinetic factors control effici ...... f human immunodeficiency virus
@en
type
label
Kinetic factors control effici ...... f human immunodeficiency virus
@ast
Kinetic factors control effici ...... f human immunodeficiency virus
@en
prefLabel
Kinetic factors control effici ...... f human immunodeficiency virus
@ast
Kinetic factors control effici ...... f human immunodeficiency virus
@en
P2093
P2860
P1433
P1476
Kinetic factors control effici ...... f human immunodeficiency virus
@en
P2093
David Kabat
Emily J Platt
James P Durnin
P2860
P304
P356
10.1128/JVI.79.7.4347-4356.2005
P577
2005-04-01T00:00:00Z